Asia Pacific

Ganfeng Lithium is set to raise HK$3.3bn ($421.6m) from its Hong Kong IPO on Thursday after pricing shares at the low end of expectations.

As the clock ticks down to the end of 2018, Asia’s debt issuers and bankers are hoping for a rebound in supply. But they have to first face a number of challenges, writes Addison Gong.

South Korea’s IPO market is struggling to gain momentum, buffeted by a drop in the benchmark equity index and an increase in surveillance of listing hopefuls by the financial regulator. With the market expected to remain fragile, caution appears to be the way to go, writes Jonathan Breen.

A dearth of corporate bond supply on Wednesday, due to a German public holiday, was followed by deals from airport operators in two markets on Thursday. Aéroports de Paris (AdP) opted for the domestic route, while Heathrow made its first visit to the Australian market.

CapitaLand has raised a S$300m ($218m) sustainability-linked loan from DBS, the first of its kind from Asia’s real estate sector.

India’s UPL Corp has launched a $3bn five year term loan into general syndication to support its acquisition of Arysta LifeScience.

We can all agree that very few conferences can be called exciting, but they are always a good excuse to get away from your desk, hear a few new ideas and catch up with the competition over cocktails.

China’s Ministry of Finance will hold its second offshore renminbi (CNH) bond auction of the year on October 10, when it will tap its first transaction from July. The new Rmb5bn offering will come two weeks after the People’s Bank of China announced plans to also start issuing CNH-denominated bills in Hong Kong.

Jack Ang is leaving his position as director of bond syndicate at Société Générale to join ANZ, GlobalCapital Asia understands.

The Hong Kong Stock Exchange is looking to boost governance of listed companies through a new proposal, but is this in the best interest of shareholders? Clawback columnist Philippe Espinasse has his say.

Fortune Choice is tapping the offshore loan market for a HK$5.2bn ($664m) fundraising to support the development of a residential building in Hong Kong.

Innovent Biologics is gauging investor appetite for an IPO in Hong Kong that could hit screens by mid-next week, according to a banker on the trade.